Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

but the drug is not approved for this specific use. To learn about therapies for weight management, talk with your doctor. Will I have hair loss with Rybelsus? It may be possible. While hair loss ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

The European Medicines Agency announced on Friday that its safety committee has concluded that Novo Nordisk’s (NVO) ...

Because Rybelsus isn’t recommended for weight loss, the drug’s manufacturer doesn’t provide recommended dosages for this use. Wegovy (semaglutide) is a GLP-1 agonist that’s specifically ...

As medications like Ozempic transform the health of millions of Americans, some families are discovering a surprising side ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...